Average Wholesale Price (AWP)

November 17th, 2017 - David Berky
Categories:   Drugs|Pharmaceuticals|FDA  
0 Votes - Sign in to vote or comment.

Find-A-Code's WK Drug Database product is becoming more and more popular and we often get asked how the AWP or average wholesale price is derived.  The following information is directly out of a Wolters Kluwer (WK) PDF file about the drug pricing:

Clinical Drug Information, LLC Average Wholesale Price (AWP) is intended only to be used by Clinical Drug Information, LLC customers. While many use this information as a price index, the Clinical Drug Information, LLC AWP does not represent an average of wholesale prices from any group of transactions in the marketplace. A wholesaler may agree to sell its products to one or more of its customers at a lower price through the use of any number of methods (i.e. discounts or rebates).

For a complete explanation of Clinical Drug Information, LLC’s AWP Policy, go to http://www.medispan.com/common/pdf/wkh_AWP_policy.pdf

Reviewing the AWP Policy carefully in its entirety is strongly encouraged, both before using the pricing contained in Wolters Kluwer Clinical Drug Information products and when making ongoing decisions about reasonable and appropriate uses of that information.

As a condition to Clinical Drug Information, LLC publishing the AWP of a product, the manufacturer must supply at least one of the following price types:

  • Suggested Wholesale Price (SWP)
  • Wholesaler Acquisition Cost (WAC)
  • Direct Price (DP)

In all cases where the manufacturer supplies an SWP, even if accompanied by either or both a WAC or DP, the AWP value will reflect the manufacturer’s SWP as reported to Clinical Drug Information, LLC. In all cases where the manufacturer does not supply an SWP, the AWP results from applying a markup to the manufacturer’s reported WAC or DP. DP is only used to determine AWP when the manufacturer does not supply a WAC. The markup applied to the WAC or DP for active products is based either on a standard markup of 20% or from certain historical, wholesaler-reported data where the historical markup is less than 20%.

This AWP pricing policy governs pricing information published in documentation manuals of other Clinical Drug Information, LLC products.

Click here for more information about the WK Drug Database product.


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

​​Polysomnography Services Under OIG Scrutiny
September 2nd, 2021 - Raquel Shumway
The OIG conducted a study dated June 2019 wherein they indicated that there were approximately $269 million in overpayments for polysomnography services for the period of 2014 through 2015. According to the OIG “These errors occurred because the CMS oversight of polysomnography services was insufficient to ensure that providers complied with Medicare requirements and to prevent payment of claims that didn’t meet those requirements.” So what are those requirements?
Medicare Advantage - The Fastest Growing Government-Funded Program Undergoing Multiple Fraud Investigations
August 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Medicare Advantage is the fastest growing form of government-funded healthcare and the rate of fraud within this segment has come under increased scrutiny. Funding is determined by the health status of each beneficiary; therefore, accurate coding based on detailed documentation makes the medical record vital to the process because some ...
Billing Dental Implants under Medical Coverage
August 12th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Implants can be costly to the patient and the provider, and it is crucial to understand how to bill a patient’s medical insurance to ensure there is adequate coverage for the best treatment. Implants are commonly billed in a dental office under a patient’s medical benefits.    Implants could be considered ...
New Codes for COVID Booster Vaccine & Monoclonal Antibody Products
August 10th, 2021 - Wyn Staheli, Director of Research
New codes have been announced for the COVID-19 booster vaccine, Novavax vaccine, and monoclonal antibody treatment.
Medicare's ABN Booklet Revised
July 29th, 2021 - Wyn Staheli, Director of Research
The “Medicare Advance Written Notices of Non-coverage” booklet, published by CMS’s Medicare Learning Network, was updated. This article discusses the changes to this booklet regarding the use of the ABN.
Chronic Pain Coding Today & in the Future
July 19th, 2021 - Wyn Staheli, Director of Research
Properly documenting and coding chronic pain can be challenging. As is commonly the case with many conditions, over the years, there has been a shift in the identification of different types of pain, including chronic pain. Understanding where we are now and where we are going will help your organization prepare for the future by changing documentation patterns now.
How Does Global and Professional Direct Contracting (GPDC) Affect Risk Adjustment?
July 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
CMS recently announced the 53 Direct Contracting Entities (DCEs) that will be participating in the April 1, 2021 through December 31, 2021 Global and Professional Direct Contracting (GPDC) Model. Among those participating is Clover Health Partners, who runs an in-home primary care program that has the potential to help Medicare ...

Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association